<DOC>
	<DOCNO>NCT02996773</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy substitute day +4 cyclophosphamide post-transplant bendamustine myeloablative ( MAC ) reduce intensity conditioning ( RIC ) haploidentical hematopoietic cell transplantation ( HHCT ) advance leukemia lymphoma patient . The phase I component study evaluate safety completely substitute second dose post-transplant cyclophosphamide ( PT-CY ) give day +4 bendamustine ( PT-BEN ) . The phase II component study continue evaluate safety efficacy subject receive PT-CY day +3 PT-BEN day +4 . Approximately , total 32 subject treat protocol . Approximately 12 15 subject use control , subject receive PT-BEN , direct comparison .</brief_summary>
	<brief_title>Haploidentical BMT With Post-Transplant Cyclophosphamide Bendamustine</brief_title>
	<detailed_description>This study follow standard-of-care bone marrow transplant ( BMT ) , exception gradually substitute post-transplant cyclophosphamide ( day +4 BMT ) bendamustine . Three dose level plan phase I component study , consist combination sequentially reduced dos cyclophosphamide increase dos bendamustine ( day +4 BMT ) full dose cyclophosphamide day +3 BMT remain unchanged . Control patient patient decline participate main trial receive haploidentical BMT current standard two day PT-CY ( PT-BEN ) consent immune monitoring study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Be willing able provide write consent/assent trial . Diagnosed one follow highrisk malignancy , require hematopoietic cell transplantation ( HCT ) available Human Leukocyte Antigen ( HLA ) match related unrelated donor acceptable cord blood High risk acute lymphoblastic leukemia ( ALL ) 1st complete remission ( CR1 ) great High risk acute myelogenous leukemia ( AML ) CR1 great High risk myelodysplastic syndrome ( MDS ) Chronic Myelogenous Leukemia ( CML ) fail intolerant Tyrosine Kinase Inhibitors ( TKIs ) accelerate , blastic phase , second subsequent chronic phase Juvenile Myelomonocytic Leukemia ( JMML ) Lymphoma , ( Hodgkin NonHodgkins Lymphoma include marginal zone , follicular lymphoma , chemotherapysensitive largecell , mantle cell lymphoma , gray zone , Burkitt 's lymphoma remission ) . At least one haploidentical relate donor available bone marrow harvest . Molecular base HLA type HLAA , B , Cw , beta chain ( DRB1 ) DQ Beta 1 Locus ( DQB1loci ) resolution need establish haploidentity . A minimum match 5/10 require . No availability 8/8 HLAmatched relate unrelated donor clinical urgency transplant ( e.g. , need within 48 week ) time acceptable unrelated donor available . Refractory acute leukemia ( &gt; 5 % blast ) progressive disease Untreated progressive central nervous system leukemia Refractory chemotherapy lymphoma Comorbidities preclude patient 's ability tolerate BMT Aspartate Aminotransferase ( AST ) / Alanine Aminotransferase ( ALT ) &gt; 5 x upper limit normal ( ULN ) Direct Bilirubin &gt; 3 x ULN Creatinine great &gt; 2 x ULN age creatinine clearance/glomerular filtration rate ( GFR ) &lt; 40 ml/min/1.73m2 Pulmonary function : Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % normal O2 Sat &lt; 92 % Cardiac : leave ventricular ejection fraction &lt; 35 % Active infection document fungal infection within 3 month BMT HIV positive Karnofsky score ( adult ) &lt; 60 % Lansky score &lt; 50 % ( pediatrics ) . Please refer section 25 protocol Karnofsky/Lansky assessment . Positive pregnancy test woman childbearing age . Severe psychiatric illness mental deficiency make compliance treatment unlikely and/or inform consent impossible . Any reason , investigator 's discretion , participation patient protocol would patient 's best interest , patient would unable adhere study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>high-risk malignancy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Haploidentical</keyword>
	<keyword>Bone Marrow Transplant ( BMT )</keyword>
	<keyword>Post-transplant</keyword>
	<keyword>myeloablative ( MAC )</keyword>
	<keyword>reduce intensity conditioning ( RIC )</keyword>
	<keyword>haploidentical hematopoietic cell transplantation ( HHCT )</keyword>
	<keyword>Leukemia</keyword>
</DOC>